Our Pipeline
Our Pipeline
Explore our Programs
Therapeutic Programs
Program
Discovery
Preclinical
IND-Enabling
Partner Program
IMTO 4842
Acute Myeloid Leukemia (AML)
Biologic I ADC
CMC and Pre-Clinical Development | 2026
IMTO 5727
Solid Tumors
Biologic
IMTO 3437
TKI-Resistant NSCLC
Biologic
Therapeutic Programs
Discovery
Preclinical
IND-Enabling
IMTO 4842
Acute Myeloid Leukemia (AML)
Biologic I ADC
CMC and Pre-Clinical Development | 2026
IMTO 5727
Solid Tumors
Biologic
IMTO 3437
TKI-Resistant NSCLC
Biologic
Therapeutic Programs
Discovery
Preclinical
IND-Enabling
IMTO 4842
Acute Myeloid Leukemia (AML)
Biologic I ADC
CMC and Pre-Clinical Development | 2026
IMTO 5727
Solid Tumors
Biologic
IMTO 3437
TKI-Resistant NSCLC
Biologic
Discover the science behind our assets
Explore the innovation underpinning our breakthroughs—dive into the details of our cutting-edge target and antibody discovery platforms
Learn More
Discover the science behind our assets
Explore the innovation underpinning our breakthroughs—dive into the details of our cutting-edge target and antibody discovery platforms
Learn More
Discover the science behind our assets
Explore the innovation underpinning our breakthroughs—dive into the details of our cutting-edge target and antibody discovery platforms
Learn More
© Copyright 2025 Immuto Scientific. All rights reserved.
© Copyright 2025 Immuto Scientific. All rights reserved.
© Copyright 2025 Immuto Scientific. All rights reserved.
